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In this pilot study we assessed patient compliance and acceptability of data recorded in the home environment by 
asthmatics using a Vitalograph a 2110 spirometer which measures peak expiratory flow rate (PEFR) and forced 
expiratory volume in 1 s (FEV,). This meter automatically time and date stamps all measurements and can also 
assess the technical acceptability of results. Data are uploaded to a personal computer for review and analysis. We 
recruited 30 patients (10 male and 20 female, age range 21-72 years) from the chest clinic at Guy’s Hospital (n=20) 
and from a GP clinic (n= 10). Patients were asked to record spirometry data using the meter at set times (8.00 a.m. 
and 8.00 p.m.) for 2 weeks. The spirometer incorporated an alarm to remind patients to take measurements. 
All patients completed the study. Mean (SD) compliance with spirometer use was 100.8% (49.9%). Nineteen 
patients had a compliance rate of between 80% and 120% of expected use. Timing of recordings was compared with 
the scheduled times of 8.00 a.m. and 8.00 p.m. Values recorded within & 2 h were judged as acceptable. For morning 
recordings 67.4% of all values and for evening recordings 71.7% of all values met this criterion. Technical 
acceptability of spirometry data was also assessed by using quality assurance criteria recorded by the spirometer. 
Valid tests were performed for 75.2% of all recordings. Twenty-two patients performed valid tests for 80-100% of 
the time. We suggest that the use of an electronic meter in the home environment is practical and is likely to generate 
more accurate and reliable data. 
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Introduction 
Asthma is a common illness and most physicians dealing 
with this disease find monitoring patients one of the difficult 
aspects of management. Even the British Thoracic Society 
guidelines on the management of asthma (1) have no 
criteria for monitoring the symptoms. Asthma symptoms 
can be monitored by various ways, by keeping a record of 
symptoms on a diary card or by home monitoring of peak 
expiratory flow rate (PEFR) and the data obtained is often 
used in clinical trials. A diary card is not always reliable (2), 
and PEFR is not always accurate (336) and also depends on 
patients’ technique and regular entry on the diary card, 
whereas it is easy to detect an unsatisfactory FEV,. 
Peak flow meters do not always detect clinically import- 
ant reductions in PEFR (7,8), and a peak flow meter 
measures only one variable which makes reliable assess- 
ment of the disease difficult. A spirometer can measure 
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serial PEFR as well as FEV, which can provide evidence of 
disease progression (9). 
We evaluated the ability of patients with asthma to use a 
Vitalograph@ 2110 hand-held spirometer in the home 
environment. Our aims were to: (a) improve the accuracy of 
home monitoring of asthma symptoms; (b) achieve better 
overall management of asthma and (c) achieve better 
patient compliance, which is an essential part of asthma 
management (10-12). There are various types of hand-held 
spirometers available which can be used to record PEFR 
and FEV, including Micro Spirometer, Escort Spirometer, 
Pocket Spirometer and Respiradyne (13316). Certain 
spirometers can record the data which can be transmitted 
by telephone to a receiving centre (17). 
Vitalograph@ 2110 is very light hand-held spirometer 
which not only records the PEFR and FEV, but can also 
record the patients symptoms and use of /&-agonist, as 
rescue therapy. This spirometer also time and date stamps 
all measurements and assesses the technical acceptability of 
results by measuring the time taken to attain peak flow 
(between 40 and 300 ms indicating a valid test). We cor- 
rected the spirometry by using the back extrapolation 
method as defined by the American Thoracic Society (ATS) 
and ERS standards (18-19). Vitalograph@ 2110 has been 
tested against ATS waveform generators and therefore fully 
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complies with ATS recommendations for spirometry. Simi- 
larly physiological tests carried out on volunteers were also 
comparable to laboratory based spirometry. 
Patients and Methods 
The study was approved by the local ethics committee. The 
duration of study was 2 weeks, involving 30 patients (Guy’s 
Hospital, n=20 and GP clinic, n=lO) with asthma to 
measure their lung function at home. Both group of 
patients were comparable in demographic details and sever- 
ity of disease. Patients completed a screening visit to assess 
suitability for the study and were enrolled after informed 
written consent, using the following criteria: (a) males and 
females aged between 18 and 65 years; (b) documented 
history of asthma; (c) patients taking treatment for asthma; 
(d) good understanding of spirometric technique; (e) able 
to perform acceptable and reproducible tests using the 
Vitalograph@ 2110 and (I) willing and able to give written 
informed consent. 
The following criteria were used to exclude patients from 
the study: (a) evidence of any clinically significant cardio- 
vascular, haematological, endocrine, hepatic, renal, gastro- 
intestinal, neurological, or psychiatric abnormalities or 
diseases; (b) significant non-reversible pulmonary diseases, 
e.g. cystic fibrosis, bronchiectasis, emphysema. 
After evaluation of spirometry technique using the 
Vitalographa 2110 meter, each patient was issued with a 
study number in numerical order. Patients were given 
both verbal and written instructions on, how to make the 
necessary assessments: 
(I) Begin taking FEV, and PEFR measurements using the 
meter on the evening of the first day of the study period and 
continue to take measurements morning and evening 
(8.00 a.m. and 8.00 p.m.) until the next clinic visit. 
(II) Record asthma symptom scores each evening using the 
meter. Asthma symptoms of wheezing, shortness of breath, 
chest tightness and cough were assessed using the following 
score: 
0 = Not present 
1 = Symptoms present but caused little or no discomfort 
2=Mild symptom that became annoying, but caused little 
or no discomfort 
3 = Moderate symptom that caused discomfort, but did not 
affect normal daily activities 
4=Severe symptom that interfered at least once in a day 
with normal daily activities 
5 = Symptom so severe that patient could not go to work/ 
school or carry out other normal daily activities. 
The meter only recorded scores within the range O-4. 
Patients wishing to award a score of 5 to any symptoms 
were instructed to contact the investigator immediately (at 
the telephone number stated on the Alert Card). 
(III) Record asthma sleep disturbance score each morning 
using the meter. Sleep disturbance caused by asthma was 
assessed by the patients using the following scale 
O=No significant asthma symptoms during the night 
1 =Asthma symptoms causing waking once or early waking 
2=Asthma symptoms causing waking twice or more 
(including waking early) 
3=Asthma symptoms causing you to be awake for most of 
the night 
4=Asthma symptoms so severe that you did not fall asleep 
at all. 
Patients wishing to award a score of 4 to sleep disturbance 
should record this score on the meter but must also contact 
the investigator immediately. 
(IV) Record, using the meter, each time a puff of inhaled 
&agonist was taken and the importance of recording 
patients rescue inhaler was stressed. Each activation of the 
meter only recorded a single puff of medication. If the 
patient took two puffs of inhaled &agonist the meter must, 
therefore, be activated twice in succession. 
Patients were instructed to withhold from taking their 
prescribed therapy (including &-agonist inhaler) until after 
completion of morning and evening FEV, and PEFR 
measurements. 
At the end of the study period, patients returned to the 
clinic, where the data which they had recorded on the 
Vitalograph@, was down loaded on a computer for review 
and patients completed a questionnaire on the device 
usability. The following variables were also evaluated on 
the last visit: (a) completeness of entries by the patient at 
home, including the symptom score and the use of rescue 
inhaler; (b) accuracy of timing of measurement by the 
patient; (c) usability of hand-held instrument by the patient 
d) usability of the system by the staff. 
Results 
Thirty patients were enrolled, with male:female ratio of 1:2. 
The mean age was 38 (21-72) years and mean compliance 
was 100.8 (49.9)%, whereas 19 patients had compliance rate 
of 8&120% of expected use. Patients were expected to use 
the spirometer twice daily for a period of 2 weeks. The 
number of occasions on which the patient actually used the 
spirometer was calculated and was expressed as percentage 
of the expected frequency of usage. Some patients therefore 
had > 100% compliance rate (Fig. 1). The mean completion 
of symptom scores was >70% (Table 1). 
Patients were defined as having satisfactory compliance 
during a given period if they had exactly two assessments 
per day, within f 2 h of the scheduled assessment time. 
Acceptable timings (values recorded within 2 h of 8.00 a.m. 
and 8.00 p.m.) for morning recordings was 67.4% and for 
evening recordings 71.7% (Table 1). 
Technical acceptability of spirometry data was assessed 
by using quality assurance criteria recorded by the spirom- 
eter (18-19). Valid tests were performed for 75.2% of 
recordings, which was technically acceptable for spirometry 
data, and 22 patients (73.3%) performed valid tests for 
S&100% (Table 2). 
The majority of patients thought that the spirometer was 
useful and they would use it again if they were given the 
opportunity (Table 2). 
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FIG. 1. Frequency of spirometry usage - categorical sum- 
mary of overall percentage compliance (n=30). 
Discussions 
Our study shows that the hand-held spirometer gives a 
more accurate assessment of disease control than conven- 
tional PEFR recording as it can record PEFR as well as 
FEV, which is a more sensitive indicator of disease control 
(9). Patients with persistent airways obstruction can have 
normal PEFR, which can potentially lead to unacceptable 
delays by the patient in seeking medical advice (8). 
We have previously shown that diary card is an unreli- 
able method of recording asthma symptom scores (2), but 
with the use of this device, recording of symptom scores 
was more accurate. Compliance can also be assessed more 
reliably than the use of a diary card, as this device is able to 
stamp the record with the date and time, which is not 
possible with conventional recording techniques. 
Another important result shown in this study was the 
record of rescue inhaler &agonist) by the patient. As 
present British Thoracic Society guidelines (1) recommend 
that the dose of inhaled corticosteroid should be increased 
if the patient is using regular rescue inhaler. We suggest that 
the use of the hand-held pocket spirometer may give a 
better assessment of compliance with therapy, as it is 
expected that patients who are recording their PEFR, FEV, 
and symptom scores are also more likely to comply with 
their treatment. 
We suggest that the use of an electronic meter such as 
Vitalograph@ 2110 in the home environment is practical 
and is likely to generate more accurate and reliable data. 
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TABLE 1. Summary statistics for overall percentage compliance, assessment times and symptom 
scores 
Overall compliance 
(%) with spirometer 
Difference between 
actual and scheduled 
assessment times (h) 
Correct completion of 
symptom score (%) 
Mean (SD) 
Median 
Minimum 
Maximum 
100.8 (49.9) 0.98 (1.01) 70.9 (32.08) 
96.4 0.82 87.5 
17.9 0.1 0 
332.1 5.3 100 
TABLE 2. Summary of valid/non-valid tests and patient questionnaire 
(a) Summary of good (valid) and bad tests - total n=935 
No. (%) of good tests 703 (75.2%) PEFR and FEV, recorded 
PEFR but no FEV, recorded 
No.(%) of bad tests 232 (24.8%) PEFR and FEV, recorded 
PEFR but no FEV, recorded 
(b) Patient questionnaire - overall assessment (n 30) 
683 (97.2%) 
20 (2.8%) 
224 (96.6%) 
8 (3.4%) 
Ql Do you think meter was useful in helping to manage your asthma? 
Very useful 6 (20.7%) Useful 14(48.3%) 
Some use 8 (27.6%) Useless 1 (3.4%) Missing 1 
Q2 Would you use the meter again if given the opportunity? 
Yes 22 (759%) No 7 (24.1%) Missing 1 
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